每经AI快讯，有投资者在投资者互动平台提问：请问贵公司的LCP中间体产品是否已经切入航空航天产 业链？每年具体营收有多少？ 建新股份（300107.SZ）1月30日在投资者互动平台表示，公司全资子公司沧州建新瑞祥化学科技有限公 司液晶高分子材料中间体目前处于试生产阶段，尚需完成生产线调试稳定及样品的客户验证等工作，因 此正式投产的时间、质量稳定性、客户接受度及对公司本年度业绩影响尚存在不确定性。公司现有产品 下游直接用户分布在染料、纸张、电子、材料等行业，不直接应用于商业航天领域，因此无法统计最终 用于商业航天领域的营收比例，公司将基于用户需求积极组织生产及开发新产品。 （文章来源：每日经济新闻） ...

格隆汇1月30日丨建新股份(300107.SZ)在投资者互动平台表示，公司全资子公司沧州建新瑞祥化学科技 有限公司液晶高分子材料中间体目前处于试生产阶段，尚需完成生产线调试稳定及样品的客户验证等工 作，因此正式投产的时间、质量稳定性、客户接受度及对公司本年度业绩影响尚存在不确定性。公司现 有产品下游直接用户分布在染料、纸张、电子、材料等行业，不直接应用于商业航天领域，因此无法统 计最终用于商业航天领域的营收比例，公司将基于用户需求积极组织生产及开发新产品。 ...

Group 1 - The company, Jianxin Co., Ltd. (300107.SZ), stated on the investor interaction platform that it has not collaborated with Blue Arrow Aerospace [1]

Group 1 - Company Sanwei Communication announced a partnership to establish a private equity fund with a total investment of 114 million yuan, with the company contributing 25 million yuan, focusing on high-tech industries such as smart manufacturing and new energy [1] - Zijin Mining plans to acquire 100% of Allied Gold Corporation for approximately 280 billion yuan, with core assets including gold mines in Mali and Ivory Coast, and an expected increase in gold production to 25 tons by 2029 [2] - Haike New Source signed a long-term cooperation agreement with BYD Lithium Battery to supply at least 100,000 tons of solvents annually for three years [3] Group 2 - China Aluminum International reported a new contract total of 468.36 billion yuan for 2025, a year-on-year increase of 51.94%, with significant growth in industrial and overseas contracts [4] - Jianxin Co. expects a net loss of 20 to 29 million yuan for 2025, compared to a profit of 19.37 million yuan in the previous year [5] - ST Dongjing anticipates a loss of 40 to 60 million yuan for 2025, an improvement from a loss of 73.45 million yuan in the previous year [6] Group 3 - Zhejiang Haideman plans to raise up to 1.517 billion yuan through a private placement for high-end machine tool projects [7] - Anlu Technology intends to raise up to 1.262 billion yuan for FPGA chip development projects [8][9] - AVIC Chengfei expects a net profit increase of 5.47% to 11.67% for 2025, projecting profits between 3.4 billion and 3.6 billion yuan [10] Group 4 - Hengtong Technology forecasts a net profit increase of 82.95% to 110.05% for 2025, with expected profits between 270 million and 310 million yuan [11] - Qingmu Technology anticipates a net profit increase of 30% to 50% for 2025, projecting profits between 118 million and 136 million yuan [13] - Zhongke Microelectronics expects a loss of 18 to 25 million yuan for 2025, marking a shift from profit to loss [14] Group 5 - Huashan Electric predicts a loss of 42 to 49.2 million yuan for 2025, compared to a loss of 26.77 million yuan in the previous year [15] - Qitian Technology expects a loss of 60 to 95 million yuan for 2025, an improvement from a loss of 214 million yuan in the previous year [16] - Sanyuan Gene announced a plan to reduce its shareholding by up to 2% [17] Group 6 - Zhongxing Junye forecasts a net profit increase of 134.32% to 173.37% for 2025, with expected profits between 300 million and 350 million yuan [18] - Shengshi Technology anticipates a net profit decrease of 50.26% to 64.55% for 2025, projecting profits between 62 million and 87 million yuan [19] - Lante Optical expects a net profit increase of 70.04% to 81.38% for 2025, with projected profits between 375 million and 400 million yuan [20] Group 7 - Dongfang Risen anticipates a loss of 2.3 to 2.9 billion yuan for 2025, compared to a loss of 3.436 billion yuan in the previous year [21] - Wandong Medical announced a change in leadership, electing Wang Jianguo as the new chairman [22] - Longsoft Technology expects a loss of 49 to 60 million yuan for 2025, with projected revenues between 148 million and 164 million yuan [23] Group 8 - Zongyi Co. forecasts a net profit increase of approximately 264.05% for 2025, with expected revenues of around 480 million yuan [24] - Sifang New Materials anticipates a loss of around 300 million yuan for 2025, with projected revenues of about 1 billion yuan [25] - Jiuding New Materials plans to acquire 100% of Jiuding New Energy for 39.51 million yuan [26] Group 9 - Kangyuan Pharmaceutical received approval for clinical trials of a new drug aimed at treating children's ailments [27] - Kaipu Testing announced plans for share reductions by its chairman and vice president [28] - Fengfan Co. intends to acquire 51% of Yanling Jiaye for 382.5 million yuan, with performance commitments for the next three years [29][30] Group 10 - Axin Security received a government subsidy of 6.8 million yuan [31] - Ge Microelectronics announced plans for a share reduction by a major shareholder [32] - ST Yingfit expects a loss of 24 to 31 million yuan for 2025, a reduction from a loss of 40.4 million yuan in the previous year [33] Group 11 - Fujilai forecasts a net profit increase of 282.17% to 296.8% for 2025, with expected profits between 62.7 million and 65.1 million yuan [34] - Huakong Saige anticipates a loss of 97 to 120 million yuan for 2025, a shift from a profit of 17.03 million yuan in the previous year [35] - Landun Optical expects a loss of 70 to 95 million yuan for 2025, compared to a profit of 6.49 million yuan in the previous year [36] Group 12 - ST Zhongji forecasts a loss of 35 to 55 million yuan for 2025, compared to a loss of 231 million yuan in the previous year [37] - Zhongsheng Pharmaceutical expects a profit of 260 to 310 million yuan for 2025, reversing a loss of 299 million yuan in the previous year [38] - Youkeshu reported a net loss of 13.85 million yuan for the first three quarters of 2025 [39] Group 13 - Haosheng Electronics anticipates a net profit decrease of 56.85% to 59.77% for 2025, projecting profits between 69 million and 74 million yuan [40] - Xiangyuan Cultural Tourism plans to withdraw from a low-altitude economic investment fund [41] - Guoen Co. has set a preliminary price range of 34 to 42 HKD for its H-share issuance [42]

Core Viewpoint - The company, Jianxin Co., Ltd. (300107.SZ), is expected to report a net loss attributable to shareholders ranging from -29 million to -20 million yuan for 2025, with a net loss of -31 million to -22 million yuan after excluding non-recurring gains and losses [1] Group 1: Financial Performance - The company is experiencing losses due to short-term operational pressures and the need to balance long-term strategic planning [1] - Sales of key products, including dye intermediates, paper chemicals, and pharmaceutical and agricultural intermediates, have decreased compared to the previous year, influenced by weak industry demand and intensified market competition [1] - The prices of major products have also declined to varying degrees compared to last year, leading to a decrease in profit margins [1] Group 2: R&D and Strategic Initiatives - Increased investment in new product development and upgrades to existing products has raised R&D expenses, negatively impacting current profits [1] - The company views the current performance fluctuations as a short-term phenomenon, with R&D investments gradually converting into technological reserves for future product upgrades and market expansion [1] - Future strategies include optimizing operational strategies, accurately seizing market opportunities, leveraging technological advantages to capture market share in niche segments, and implementing reforms to reduce costs and enhance efficiency [1]

Core Viewpoint - The company expects a negative net profit for the fiscal year 2025, with a projected net profit attributable to shareholders ranging from -29 million to -20 million yuan, and a net profit after deducting non-recurring gains and losses estimated between -31 million and -22 million yuan [1] Group 1: Financial Performance - The company reported a loss in performance during the reporting period, primarily due to short-term operational pressures and the need to balance long-term strategic planning [1] - The decline in sales volume for products such as dye intermediates, paper chemicals, and pharmaceutical and agricultural intermediates is attributed to weak industry demand and intensified market competition [1] - The prices of major products have decreased to varying degrees compared to the previous year, leading to a decline in profit margins [1] Group 2: Investment and R&D - Increased investment in new product development and upgrades to existing products has resulted in higher R&D expenses, negatively impacting current profits [1]

Financial Performance - The company expects a net profit of approximately -29 million CNY for the fiscal year 2025, compared to a profit of 19.37 million CNY in the same period last year[5]. - The net profit after deducting non-recurring gains and losses is projected to be around -31 million CNY, down from -22 million CNY in the previous year[5]. - Non-recurring gains and losses are expected to affect net profit by approximately 2 million CNY[8]. Market Conditions - The decline in performance is attributed to weak industry demand and intensified market competition, leading to reduced sales and price declines in key products[8]. Investment and Strategy - Increased investment in new product development and existing product upgrades has negatively impacted current profits[8]. - The company plans to optimize its business strategy and leverage technological advantages to capture market share in niche segments[8]. - Future efforts will focus on cost reduction, efficiency improvement, and product structure optimization to mitigate market risks[8]. - The company emphasizes that the current performance fluctuation is a short-term phenomenon, with R&D investments laying a solid foundation for future product upgrades and market expansion[8]. Investor Communication - Detailed financial data will be disclosed in the 2025 annual report, urging investors to make cautious decisions[9].

Market Overview - The chemical products sector experienced a decline of 0.55% on January 14, with Chenghe Technology leading the losses [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index rose to 14248.6, up 0.56% [1] Top Gainers in Chemical Sector - Qicai Chemical (300758) saw a significant increase of 20.01%, closing at 16.85 with a trading volume of 524,100 shares and a turnover of 832 million [1] - Changhua Chemical (301518) rose by 12.77%, closing at 44.60 with a trading volume of 124,200 shares and a turnover of 519 million [1] - Demei Chemical (002054) increased by 9.99%, closing at 8.81 with a trading volume of 420,300 shares and a turnover of 360 million [1] Top Losers in Chemical Sector - Chenghe Technology (688625) declined by 5.79%, closing at 58.71 with a trading volume of 88,500 shares and a turnover of 525 million [2] - Duofuduo (002407) fell by 4.31%, closing at 31.55 with a trading volume of 1,265,100 shares and a turnover of 404.6 million [2] - Kaisa Bio (688065) decreased by 3.97%, closing at 59.77 with a trading volume of 158,000 shares and a turnover of 965 million [2] Capital Flow Analysis - The chemical products sector experienced a net outflow of 1.757 billion from institutional investors, while retail investors saw a net inflow of 1.333 billion [2] - The top stocks with significant net inflows from retail investors include Qicai Chemical (300758) with a net inflow of 256 million [3] - Demei Chemical (002054) also had a notable net inflow of 108 million from retail investors [3]

Group 1 - The company, Jianxin Co., has completed the registration capital change and the filing of its Articles of Association [2] - The company has obtained a new business license issued by the Cangzhou Administrative Approval Bureau [2]

证券代码：300107 证券简称：建新股份 公告编号：2025-047 河北建新化工股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载，误导性陈述或重大遗漏。 河北建新化工股份有限公司（以下简称"公司"）分别于 2025 年 10 月 27 日、2025 年 11 月 14 日召开了第六届董事会第十五次会议和 2025 年第一次临时 股东大会，审议并通过了《关于修订<公司章程>的议案》。具体内容详见公司于 2025 年 10 月 28 日在巨潮资讯网(www.cninfo.com.cn)披露的《关于修订<公司 章程>及修订、制定部分治理制度的公告》（公告编号：2025-041），以及 2025 年 11 月 14 日在巨潮资讯网(www.cninfo.com.cn)披露的《2025 年第一次临时股 东大会决议公告》（公告编号：2025-045）。 2、统一社会信用代码:911309007502944073 3、类型：股份有限公司（上市、自然人投资或控股） 1 4、法定代表人：朱守琛 5、注册资本：伍亿陆仟贰佰柒拾捌万贰仟贰佰陆拾捌元 ...